Search Within

Karthik Nath

  1. "Myeloma"
Formats
  1. Meeting Abstract (7)
  2. Journal Article (4)
  3. Review (2)
  4. Correspondence (1)
  5. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (15)
  2. Department of Medicine (15)
  3. GME, Medicine (15)
  4. Graduate Medical Education (15)
  5. Hematologic Malignancies, Division of (15)
  6. Myeloma (15)

More Groups

People
  1. Sham Mailankody (15)
  2. Saad Usmani (12)
  3. Urvi Shah (12)
  4. Alexander Lesokhin (11)
  5. Gunjan Shah (11)
  6. Sergio Giralt (11)

More People

Years
  1. 2024 (4)
  2. 2023 (8)
  3. 2022 (3)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (5)
  2. Blood (3)
  3. Blood Cancer Journal (2)
  4. Clinical Pharmacology & Therapeutics (1)
  5. Hematology/Oncology Clinics of North America (1)
  6. Leukemia and Lymphoma (1)

More Publications

Publishers
  1. Elsevier Inc. (6)
  2. Nature Publishing Group (4)
  3. American Society of Hematology (3)
  4. Massachusetts Medical Society (1)
  5. Taylor & Francis Group (1)

Results (15)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • GPRC5D as a novel immunotherapeutic target in multiple myeloma
    Editorial

    Nath, K.; Costa, B. A.; Mailankody, S.
    Nature Reviews Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy
    Journal Article

    Van Oekelen, O.; Nath, K.; Mouhieddine, T. H.; Farzana, T.; Aleman, A.; Melnekoff, D. T.; Ghodke-Puranik, Y.; Shah, G. L.; Lesokhin, A.; Giralt, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Interventions and outcomes of multiple myeloma patients progressing after BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy
    Meeting Abstract

    Van Oekelen, O.; Nath, K.; Mouhieddine, T. H.; Farzana, T.; Aleman, A.; Melnekoff, D. T.; Ghodke-Puranik, Y.; Jagannath, S.; Shah, U. A.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Correspondence

    Nath, K.; Shekarkhand, T.; Salcedo, M.; Derkach, A.; Rueda, S.; Chansakul, A.; Hulcrantz, M.; Korde, N.; Shah, U. A.; Tan, C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save